title: Topical application of aloperine improves 2,4-dinitrofluorobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.
abstract: Aloperine has been shown to inhibit 2,4-dinitrofluorobenzene (DNFB) induced allergic contact dermatitis in BALB/c mice. In the present study, we further investigated the effect of aloperine on DNFB-induced atopic dermatitis-like skin lesions in NC/Nga mice. NC/Nga mice elicited atopic dermatitis-like skin lesions after the topical application of DNFB. Aloperine treatment significantly inhibited dermatitis index and ear thickness in DNFB-treated NC/Nga mice in a dose-dependent manner. Eosinophils, mast cells infiltration into the ears and plasma level of immunoglobulin (Ig) E were also suppressed by aloperine treatment. Finally, cytokine (interleukin (IL)-1β, IL-4, IL-6, IL-10, IL-13, tumor necrosis factor (TNF)-α and interferon (IFN)-γ) productions in ear biopsies homogenates were significantly elevated after DNFB challenge. Topical application of aloperine increased the immunosuppressive cytokine IL-10 level, while it reduced other cytokines production in a dose-dependent manner. Taken together, these data suggest that aloperine may be one of the effective therapeutic agents for the treatment of atopic dermatitis.
authors.affiliation: Department of Dermatology, General Hospital of the Air Force, Beijing 1000142, PR China.
authors.forename: Xiao-Ying
authors.initials: XY
authors.lastname: Yuan
authors.forename: Hui-Min
authors.initials: HM
authors.lastname: Ma
authors.forename: Rui-Zhi
authors.initials: RZ
authors.lastname: Li
authors.forename: Rui-Yan
authors.initials: RY
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Liu
authors.forename: Jian-You
authors.initials: JY
authors.lastname: Guo
mesh_terms: D000287:Administration, Topical; D000818:Animals; D003876:Dermatitis, Atopic / Q000139:chemically induced* / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004139:Dinitrofluorobenzene / Q000494:pharmacology*; D015536:Down-Regulation / Q000187:drug effects; D004423:Ear / Q000473:pathology; D005260:Female; D007073:Immunoglobulin E / Q000097:blood; D016753:Interleukin-10 / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology; D051379:Mice; D010880:Piperidines / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D054837:Quinolizidines; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D010880:Piperidines; D054837:Quinolizidines; D016753:Interleukin-10; D007073:Immunoglobulin E; C062701:aloperine; D004139:Dinitrofluorobenzene